225 related articles for article (PubMed ID: 11309346)
21. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
Prell RA; Li B; Lin JM; VanRoey M; Jooss K
Cancer Res; 2005 Mar; 65(6):2449-56. PubMed ID: 15781661
[TBL] [Abstract][Full Text] [Related]
22. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
23. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.
Kaplan JM; Yu Q; Piraino ST; Pennington SE; Shankara S; Woodworth LA; Roberts BL
J Immunol; 1999 Jul; 163(2):699-707. PubMed ID: 10395660
[TBL] [Abstract][Full Text] [Related]
24. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo.
Wagner SN; Wagner C; Lührs P; Weimann TK; Kutil R; Goos M; Stingl G; Schneeberger A
J Invest Dermatol; 2000 Dec; 115(6):1082-7. PubMed ID: 11121145
[TBL] [Abstract][Full Text] [Related]
25. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
26. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
27. Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.
Wang XY; Chen X; Manjili MH; Repasky E; Henderson R; Subjeck JR
Cancer Res; 2003 May; 63(10):2553-60. PubMed ID: 12750279
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
30. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine.
Mahvi DM; Burkholder JK; Turner J; Culp J; Malter JS; Sondel PM; Yang NS
Hum Gene Ther; 1996 Aug; 7(13):1535-43. PubMed ID: 8864754
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model.
Nawrath M; Pavlovic J; Moelling K
J Mol Med (Berl); 2001 Apr; 79(2-3):133-42. PubMed ID: 11357937
[TBL] [Abstract][Full Text] [Related]
32. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
33. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma.
Aravindaram K; Yu HH; Lan CW; Wang PH; Chen YH; Chen HM; Yagita H; Yang NS
Gene Ther; 2009 Nov; 16(11):1329-39. PubMed ID: 19626052
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
35. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
[TBL] [Abstract][Full Text] [Related]
36. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.
Simmons AD; Li B; Gonzalez-Edick M; Lin C; Moskalenko M; Du T; Creson J; VanRoey MJ; Jooss K
Cancer Immunol Immunother; 2007 Oct; 56(10):1653-65. PubMed ID: 17410360
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
39. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.
Weth R; Christ O; Stevanovic S; Zöller M
Cancer Gene Ther; 2001 Aug; 8(8):599-611. PubMed ID: 11571538
[TBL] [Abstract][Full Text] [Related]
40. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
